Nanobiotix S.A. (NBTX) Income Statement
NBTX 2025 at a glance
Fiscal year ended December 31, 2025 · eurosNBTX revenue and net income
Where NBTX's revenue goes
2025Each bar shows an amount and its share of revenue. NBTX kept −80.8% of revenue as net income.
NBTX profit margins
NBTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | +83.8% | +66.4% | +22.1% |
| Gross profit | — | +83.8% | +66.4% | +22.1% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NBTX income statement in euros
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €29.6M | €0 | €36.2M | €4.8M | €2.6M | €2.3M | €2.5M | €3.5M | €3.7M | €5.4M |
| Cost of revenue | €0 | €7.2M | €0 | €985,000 | €0 | €0 | €0 | €0 | €345,591 | €436,307 |
| Gross profit | €29.6M | −€7.2M | €36.2M | €4.8M | €2.6M | €2.3M | €2.5M | €3.5M | €3.7M | €5.4M |
| Research & development | €23.1M | €40.5M | €38.4M | €32.6M | €30.4M | €24.3M | €30.4M | €20.9M | €17.7M | €16.9M |
| Sales, general & admin | €20.2M | €20.1M | €22.0M | €17.5M | €19.4M | €14.3M | €18.6M | €12.6M | €12.3M | €10.3M |
| Total operating expenses | €40.5M | €61.2M | €63.0M | €51.5M | €55.2M | €38.8M | €49.3M | €33.5M | €29.0M | €27.3M |
| Operating income | −€10.8M | −€68.4M | −€26.8M | −€46.7M | −€52.6M | −€36.4M | −€46.8M | −€30.1M | −€25.3M | −€21.9M |
| Interest income | €985,000 | €2.6M | €1.2M | €256,000 | €6.2M | €4.7M | €105,000 | €1.2M | €33,026 | €59,492 |
| Interest expense | €10.4M | €8.1M | €8.0M | €5.8M | €699,490 | €333,000 | €4.8M | €847,000 | €108,367 | €102,203 |
| Income before taxes | −€24.0M | −€68.0M | −€39.6M | −€57.0M | −€47.0M | −€33.6M | −€50.9M | −€30.3M | −€26.1M | −€21.8M |
| Income taxes | €3,000 | €101,000 | €120,000 | €10,000 | €5,000 | €9,000 | €3,000 | −€449,000 | €20 | €90,425 |
| Net income | −€24.0M | −€68.1M | −€39.7M | −€57.0M | −€47.0M | −€33.6M | −€50.9M | −€30.3M | −€26.1M | −€21.9M |
| EBITDA | −€12.1M | −€66.6M | −€22.7M | −€44.2M | −€45.6M | −€34.9M | −€45.0M | −€29.4M | −€24.8M | −€21.4M |
| Gross margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −36.5% | — | −74.0% | −977.8% | −1,986.4% | −1,566.8% | −1,841.0% | −864.2% | −678.9% | −403.1% |
| Net margin | −80.8% | — | −109.6% | −1,194.3% | −1,775.7% | −1,444.7% | −2,003.7% | −872.2% | −702.4% | −403.6% |
| Jun '26 | Dec '25 | Jun '25 | Mar '25 | Jun '24 | Mar '24 | Sep '23 | Jun '23 | Mar '23 | Sep '22 | Jun '22 | Mar '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €5.6M | €3.0M | €26.6M | €0 | €9.3M | €32.9M | €16.5M | €3.3M | €3.4M | €1.7M | €1.3M | €1.3M |
| Cost of revenue | €0 | €0 | €0 | €16.5M | €0 | €27.2M | €0 | €740,000 | €754,000 | €0 | €746,000 | €759,000 |
| Gross profit | €5.6M | €3.0M | €26.6M | −€16.5M | €9.3M | €32.9M | €16.5M | €3.3M | €3.4M | €1.7M | €1.3M | €1.3M |
| Research & development | €11.8M | €8.6M | €14.5M | €18.6M | €22.0M | €20.6M | €10.3M | €17.8M | €16.0M | €8.0M | €16.6M | €14.9M |
| Sales, general & admin | — | €8.9M | — | €20.1M | — | — | — | — | — | — | — | — |
| Total operating expenses | €23.5M | €14.6M | €25.8M | €28.3M | €32.9M | €34.3M | €20.5M | €28.7M | €24.3M | €15.6M | €27.2M | €24.1M |
| Operating income | −€17.9M | −€11.6M | €808,000 | −€44.7M | −€23.7M | −€1.4M | €569,500 | −€25.4M | −€20.8M | −€10.4M | −€25.9M | −€22.8M |
| Interest expense | €14.7M | €6.8M | €3.6M | €8.1M | — | €3.4M | — | €3.4M | €3.1M | — | — | — |
| Income before taxes | −€34.3M | −€18.6M | −€5.4M | −€46.3M | −€21.7M | −€11.5M | −€5.7M | −€28.1M | −€30.7M | −€15.3M | −€26.4M | −€16.6M |
| Income taxes | €16,000 | −€3,000 | €6,000 | −€43,000 | €144,000 | €117,000 | €58,500 | €3,000 | €4,000 | €2,000 | €6,000 | €3,000 |
| Net income | −€34.7M | −€18.6M | −€5.4M | −€46.3M | −€21.9M | −€11.6M | −€5.8M | −€28.1M | −€30.7M | −€15.3M | −€26.4M | −€16.6M |
| EBITDA | −€19.3M | −€13.6M | €1.6M | −€43.9M | −€22.7M | €1.9M | €706,500 | −€24.6M | −€20.0M | −€10.3M | −€24.2M | −€22.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | −322.9% | −386.9% | 3.0% | — | −254.6% | −4.3% | 3.5% | −770.4% | −604.1% | −603.4% | −1,947.1% | −1,716.9% |
| Net margin | −626.0% | −618.2% | −20.2% | — | −235.5% | −35.2% | −35.2% | −853.3% | −890.2% | −890.2% | −1,983.2% | −1,248.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in euros as reported in NBTX's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NBTX financial results
In fiscal year 2025 (ended December 31, 2025), Nanobiotix reported revenue of €29.6 million. It had a net loss of €24.0 million, a net profit margin of −80.8%. Over five years revenue grew at an average rate of 66.4% a year. Figures are in euros, the currency of its financial statements.
See the NBTX stock overview for the latest quote and news, or the NBTX chart for price history and technical indicators.
NBTX income statement FAQ
What is Nanobiotix's annual revenue?
Nanobiotix reported total revenue of €29.6 million for fiscal year 2025, which ended on December 31, 2025.
Is Nanobiotix profitable?
No. Nanobiotix reported a net loss of €24.0 million in fiscal 2025, a net profit margin of −80.8%; its operating margin was −36.5%.
What is Nanobiotix's gross margin?
Nanobiotix's gross margin was 100.0% in fiscal 2025: for every $100 of revenue, Nanobiotix kept $100 after the direct cost of its products and services.
How much does Nanobiotix spend on research and development?
Nanobiotix spent €23.1 million on research and development in fiscal 2025, 78.0% of revenue.
How fast is Nanobiotix growing?
Revenue grew 66.4% a year on average over the last five fiscal years, from €2.3 million to €29.6 million.
When does Nanobiotix's fiscal year end?
Nanobiotix's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.